soul trial oral semaglutide cardiovascular outcomes results 2024 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM NEJM Editorial Fellow Harleen Marwah,
Pay in 4 interest-free payments of $6.74 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Live Spec
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Visit NEJM.org for the full trial results. #ACC25 #Cardiology #ClinicalTrials #MedTok #NEJM Trial Scorecard: SOUL The SOUL Study by J Gamble, PhD RPh Oral Semaglutide 25 mg delivers double digit weight loss in OASIS 4 (Phase 3 trial) Just out in NEJM: A 71 week RCT tested oral semaglutide 25 mg daily in adults The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial Request PDF The Role of Glucagon Like Peptide 1 Receptor Agonists in the Treatment of Cardiovascular Kidney Metabolic Syndrome JACC: Advances
Store: www.ab-travaux.com · Domain: www.ab-travaux.com



























